ImpediMed, a Carlsbad, CA-based company which specializes in medical technologies to clinically monitor and manage fluid and body composition, raised $15M in growth funding.
Backers included SWK Holdings (NASDAQ:SWKH).
The company intends to use the funds to support the continued execution of its commercial strategy.
Led by Dr. Parmjot Bains, MD, CEO and Managing Director, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate data to optimize patient health. It produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.
The company was founded in Brisbane, Australia.
FinSMEs
10/02/2025